Ada, Ahmet OğuzKunak, Celalettin SemihBilgen, SerdarAlpar, SibelGülhan, Meral2021-06-232021-06-2320100028-2685https://doi.org/10.4149/neo_2010_06_512https://hdl.handle.net/20.500.12491/4097Several polymorphisms in cytochrome P-450s (CYP)s and Glutathione S-transferases (GST)s have been reported to be associated with survival rates of patients with non-small cell lung cancer (NSCLC) but the studies in this regard are scarce and the results are contradictory. In this study, CYP1A1 (Ile462Val), CYP1B1(Asn453Ser), GST M1, GSTP1 exon 5 (Ile105Val) and exon 6(Ala114Val) and GSTT1 polymorphisms were determined in 138 patients with advanced NSCLC to evaluate their role in survival. Of the studied CYP and GST polymorphisms only GSTP1 exon 6 variant significantly altered (improved) the survival compared to wild type (p=0.036) with median survival of 22.2 months and 16.1 months, respectively. Multivariate analysis also revealed a significant reduction of adjusted hazard ratio of death associated only with the GSTP1 exon 6 variant genotype of 0.45 (95% confidence interval (95% CI), 0.23-0.89, p=0.022). These results show that the GSTP1 exon 6 variant genotype is associated with improved survival in the patients with advanced NSCLC.eninfo:eu-repo/semantics/openAccessCytochrome P-450Glutathione S-TransferaseNon Small Cell Lung CancerPolymorphismSurvivalArticle10.4149/neo_2010_06_512576512521208459892-s2.0-79952113910Q2